Clinical trial

Metabolism Informed Smoking Treatment in Medicaid and Medicare Patients: The MIST RCT

Name
VICC THO 2046
Description
This phase 3 randomized controlled trial will test Metabolism-Informed Smoking Treatment (MIST), a precision approach to smoking treatment that biologically tailors medication selection to nicotine metabolism.
Trial arms
Trial start
2020-11-17
Estimated PCD
2025-11-01
Trial end
2026-11-01
Status
Active (not recruiting)
Phase
Early phase I
Treatment
Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.
Automated calls to assess smoking status, medication use, and additional support for quit attempt.
Arms:
MIST (Metabolism-Informed Smoking Treatment), Usual Care
Nicotine Replacement Therapy
FDA-approved forms of nicotine replacement therapy for smoking cessation.
Arms:
MIST (Metabolism-Informed Smoking Treatment), Usual Care
Varenicline
FDA-approved smoking cessation medication.
Arms:
MIST (Metabolism-Informed Smoking Treatment), Usual Care
Other names:
Chantix
Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)
Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy. NMR is a blood test to measure how fast the body breaks down nicotine.
Arms:
MIST (Metabolism-Informed Smoking Treatment)
Size
608
Primary endpoint
Biochemically-validated past 7-day point prevalence tobacco abstinence
6 months
Eligibility criteria
Inclusion Criteria: * be 18 years or older * be enrolled in an insurance plan that supports prescription coverage for smoking cessation medication (such as Medicare part D, Medicaid, or private insurance) to facilitate bedside delivery of medications prior to hospital discharge * have a regular provider/PCP * agree to quit or try to quit smoking upon hospital discharge * be a daily smoker when smoking normally during the month prior to entering the hospital * be medically eligible to use varenicline * be medically eligible to use nicotine replacement therapy * have received discharge medication recommendations from a tobacco counselor * agree to take smoking cessation medication (i.e., varenicline OR nicotine replacement therapy) home and consider using it * have a cell phone or landline that can be reached directly (i.e., without transfer) * have a permanent address where they live and can receive mail * estimated life expectancy of at least one year or greater Exclusion Criteria: * insufficient time to perform and complete the enrollment process * barrier to effective communication (including low English proficiency) * not cognitively able to participate in the study * too ill, on hospice, or physically unable to participate in the follow-up process * previously completed the MIST study or is currently enrolled in a quit smoking study that involves a medication-based treatment * estimated life expectancy of less than one year
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 608, 'type': 'ACTUAL'}}
Updated at
2023-11-13

1 organization

2 products

1 indication